Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

Core Viewpoint - Tivic Health Systems Inc. has secured a non-clinical evaluation agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to conduct preclinical studies on Entolimod for gastrointestinal acute radiation syndrome (GI-ARS) [2][4]. Group 1: Agreement and Study Details - The agreement allows NIAID to fund and conduct studies at the Armed Forces Radiobiology Research Institute (AFRRI) to evaluate Entolimod's efficacy in protecting GI tissue from radiation-induced damage [4][6]. - The initial studies will utilize mouse models, with potential advancement to non-human primate studies if initial results are promising [5]. Group 2: Strategic Importance - The development of Entolimod is seen as a critical advancement in addressing the treatment gap for acute radiation syndrome, particularly for gastrointestinal injuries, which are not effectively targeted by existing therapies [7][8]. - Currently approved therapies primarily focus on the hematopoietic system, leaving a significant unmet need for GI protection [8]. Group 3: Mechanism and Regulatory Pathway - Entolimod acts as a Toll-like receptor 5 (TLR5) agonist, activating NF-kB signaling pathways to potentially protect multiple tissue types from radiation damage [9][11]. - The studies are designed to support regulatory approval under the FDA's Animal Rule, facilitating an expedited Biologics License Application (BLA) submission [9][10]. Group 4: Company Overview - Tivic Health is focused on developing biologics that activate innate immune pathways for cytoprotection and modulate immune responses in various conditions, including radiation exposure [10]. - The company is also advancing Entolasta, a next-generation TLR5 agonist aimed at broader therapeutic applications, including oncology supportive care [12].